Global Measles Vaccine Market Size By Type (Mumps Measles Rubella Vaccine, Live (MMR-II)), By Application (Children, Adults), By Region, And Segment Forecasts, 2023 to 2032

The Global Measles Vaccine Market was valued at USD 2.1 billion in 2023 and is projected to reach USD 3.7 billion by 2031, expanding at a CAGR of 7.1% during the forecast period from 2023 to 2031. The growth of the market is primarily driven by increasing immunization campaigns, government support for universal vaccine coverage, and the resurgence of measles outbreaks in certain regions. Measles, a highly contagious viral disease, can be effectively prevented through timely vaccination. With a growing emphasis on childhood immunization and global health security, demand for measles vaccines is expected to remain robust over the next decade.

Drivers:

1. Rising Government and WHO-led Immunization Initiatives:

Global vaccination programs led by organizations such as WHO, UNICEF, and Gavi are significantly enhancing access to measles vaccines, particularly in low-income countries.

2. Resurgence of Measles Outbreaks:

A resurgence in measles outbreaks in both developed and developing countries has underscored the need for stronger vaccine coverage, leading to increased demand.

3. Increased Global Awareness and Public Health Spending:

Rising awareness about the consequences of vaccine-preventable diseases and increased investments in public health infrastructure are bolstering measles vaccine uptake.

Restraints:

1. Vaccine Hesitancy and Misinformation:

Public mistrust and the spread of vaccine-related misinformation on social media continue to impede vaccine acceptance in some regions.

2. Cold Chain and Storage Challenges:

The requirement for stringent cold chain logistics in remote and underdeveloped areas increases the operational cost and complexity of vaccine distribution.

Opportunity:

1. Technological Advancements in Vaccine Formulations:

New formulations that offer improved efficacy, longer shelf life, and ease of administration are likely to boost market growth.

2. Expansion into Emerging Markets:

Growing healthcare infrastructure and rising immunization budgets in regions like Africa, Southeast Asia, and Latin America present significant growth opportunities for vaccine manufacturers.

Market by System Type Insights:

By system type, the Monovalent Measles Vaccine segment held the largest market share in 2023, due to its direct efficacy against the measles virus and widespread use in early immunization schedules. However, the Combined MMR (Measles, Mumps, Rubella) Vaccine segment is expected to witness faster growth owing to its broader coverage, convenience, and increasing adoption in national immunization programs.

Market by End-Use Insights:

Based on end-use, Pediatric applications dominated the market in 2023, accounting for more than 80% of the revenue share. Infants and young children are the primary demographic for measles vaccination under national and international immunization schedules. The Adult & Travel Vaccination segment is expected to grow steadily, driven by rising adult immunization awareness and requirements for travelers visiting endemic areas.

Market by Regional Insights:

Asia-Pacific led the global measles vaccine market in 2023, primarily due to large-scale immunization drives in densely populated countries like India and China. Africa is projected to exhibit the highest CAGR during the forecast period, supported by increased funding and government partnerships with international health agencies. North America and Europe remain significant contributors, driven by robust healthcare systems and strong vaccine mandates.

Competitive Scenario:

Key players in the global measles vaccine market include Merck & Co., Inc., GlaxoSmithKline plc, Serum Institute of India Pvt. Ltd., Sanofi Pasteur, Bharat Biotech, and Zydus Cadila. These companies are focused on expanding their global reach through strategic collaborations, government contracts, and advancements in vaccine technology.

Recent Developments:

In 2023, Merck announced an expansion of its vaccine manufacturing facility to meet global demand.

Serum Institute of India entered a partnership with Gavi in 2024 to supply cost-effective measles vaccines to Africa and Southeast Asia.

GlaxoSmithKline launched an improved MMR vaccine formulation with enhanced thermal stability in 2023.

Scope of Work – Global Measles Vaccine Market

Report Metric Details

Market Size (2023) USD 2.1 billion

Projected Market Size (2031) USD 3.7 billion

CAGR (2023–2031) 7.1%

Market Segments By System Type, End-Use, Region

Growth Drivers Global immunization campaigns, resurgence of measles outbreaks, increased public health spending

Opportunities Emerging markets expansion, advanced vaccine formulations

Key Market Developments:

2023: Merck began the development of a thermostable measles vaccine formulation to improve rural distribution.

2024: Bharat Biotech launched a low-cost MMR vaccine aimed at Southeast Asia and African countries.

2025: Sanofi Pasteur announced a joint venture with UNICEF to improve vaccine supply chains in Latin America.

FAQs:

1) What is the current market size of the Global Measles Vaccine Market?

The Global Measles Vaccine Market was valued at USD 2.1 billion in 2023.

2) What is the major growth driver of the Global Measles Vaccine Market?

The primary growth driver is the increasing number of global immunization campaigns and resurgence of measles outbreaks.

3) Which is the largest region during the forecast period in the Global Measles Vaccine Market?

Asia-Pacific is projected to remain the largest regional market during the forecast period.

4) Which segment accounted for the largest market share in the Global Measles Vaccine Market?

The Pediatric segment accounted for the largest market share in 2023.

5) Who are the key market players in the Global Measles Vaccine Market?

Key players include Merck & Co., Inc., GlaxoSmithKline plc, Serum Institute of India, Sanofi Pasteur, Bharat Biotech, and Zydus Cadila.